Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas File

Infectious Disease Akron, OH Medical Doctor

NPI 1366529091 CMS profile 61577

75 Arch St., Ste. 506, Akron, OH 44304

Open in the dashboard

General payments

$68,457

226 records reported · program years 2019–2025

Research payments

$3,200

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas File of Akron, OH is reported in the CMS Open Payments database as having received $68,457 across 226 general payments and $3,200 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,562 24
2024 General $15,661 17
2023 General $7,856 34
2022 General $6,978 17
2021 General $268 8
2020 General $467 28
2020 Research $3,200 1
2019 General $5,666 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas File
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Thomas File were reported at $31,562. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Thomas File Infectious Disease median Middle half National median
2019 $5,666 $190 $60–$862 $163
2020 $467 $124 $32–$606 $114
2021 $268 $148 $38–$905 $132
2022 $6,978 $166 $50–$834 $149
2023 $7,856 $171 $57–$787 $160
2024 $15,661 $176 $52–$752 $164
2025 $31,562 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $23,187 41 payments
  2. Shionogi Inc $18,560 9 payments
  3. Fisher Scientific Company L.L.C. $8,944 13 payments
  4. Paratek Pharmaceuticals, Inc. $7,048 7 payments
  5. Pfizer Inc. $3,621 2 payments
  6. Nabriva Therapeutics, plc $3,337 2 payments
  7. Gilead Sciences, Inc. $1,569 63 payments
  8. Janssen Biotech, Inc. $621 30 payments
  9. Insmed, Inc. $347 6 payments
  10. ViiV Healthcare Company $306 22 payments
  11. Other $918 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $32,964 11 payments
  2. Travel and Lodging $15,708 19 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,111 2 payments
  4. Honoraria $6,700 4 payments
  5. Food and Beverage $5,914 187 payments
  6. Education $60 3 payments
Products named General payments · program years 2019–2025
  1. Fetroja $15,874 7 payments
  2. CAPVAXIVE $10,657 13 payments
  3. NUZYRA $7,048 7 payments
  4. Procalcitonin $5,865 10 payments
  5. PREVNAR 20 $3,621 2 payments
  6. Xenleta $3,337 2 payments
  7. BRAHMS PCT KRYPTOR $3,079 3 payments
  8. S-217622 $2,575 1 payment
  9. PNEUMOVAX 23 $1,462 14 payments
  10. SYMTUZA $768 27 payments
  11. Other $2,317 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $3,200 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

51

Median for Internal Medicine: 777

Drug cost

$135,904

Median for Internal Medicine: $73,373

Branded share of claims

100%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 17 $64,784
Tivicay Dolutegravir Sodium Brand 21 $43,779
Descovy Emtricitabine/Tenofov Alafenam Brand 13 $27,342

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Fetroja
  • Shionogi Inc $5,740
$5,740 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $5,133
$5,133 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record